Acute Myeloid Leukemia

2015/09/16 by Hartmut Döhner, Daniel J. Weisdorf, Clara D. Bloomfield · 2 citations
Medicine · #Acute Myeloid Leukemia Research #Myeloproliferative Neoplasms: Diagnosis and Treatment #Hematopoietic Stem Cell Transplantation #Medicine #Myeloid leukemia #Nosology #Leukemia #Myeloid #Disease #Intensive care medicine #Immunology #Internal medicine #Pathology

paper · doi:10.1056/nejmra1406184

openalex publication_date 2015/09/16 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05

Abstract

Many recent biologic insights have shed light on the nosology of acute myeloid leukemia. Although this new knowledge has not yet had a major influence on the treatment of the disease, strategies under investigation may improve outcomes.

Citations

• Targeting Epigenetic Readers in Cancer
• Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
• Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Cited by

• Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
• Acute myeloid leukemia [wikipedia]

Related

• Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
• Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
• Acute myeloid leukemia: 2019 update on risk‐stratification and management
• Acute myeloid leukemia management and research in 2025
• Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours